← Back to Test

Problem 5 - Entrance Test

A major pharmaceutical company is considering investing billions in developing a novel drug for a rare genetic disease. The company's internal analysis projects that the drug, if successful, could command a premium price due to its unique mechanism of action and the lack of existing treatments. This high price, they argue, will ensure profitability despite the small patient population and the immense research and development costs.

Correct: A

The argument hinges on the idea that the drug's projected 'premium price' will ensure profitability. To evaluate this, one must assess the feasibility and sustainability of this premium pricing strategy. Choice A directly questions whether the premium price can actually be *realized and sustained* in the market, as major payers (insurance companies, national health services) are crucial gatekeepers for drug access and pricing. If the drug's efficacy isn't high enough to justify the price in their eyes, then the projected profitability based on that premium price is severely undermined. Choice B is also important for long-term profitability but is a future contingency; A addresses the immediate viability of the pricing strategy itself. Choice C concerns ethics, not the financial argument for profitability. Choice D's information (exact patient number) is already implicitly addressed by 'small patient population'; the core uncertainty is the revenue per patient (the actual achievable price).